Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 6c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.95), $0.06 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $22.2 million versus the consensus estimate of $22.25 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
• Village Farms names interim CFO from its Canadian cannabis unit
• Redwood Trust plans $150M convertible notes offering due 2030